BJ-005 is under clinical development by BJ Bioscience and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BJ-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BJ-005 overview
BJ-005 is under development for the treatment of advanced solid tumors and lymphoma. It is a bi-functional monoclonal antibody. The drug candidate acts by targeting PD-L1 and TGF beta. It is administered through intravenous route.
BJ Bioscience overview
BJ Bioscience is a biotechnology company that develops, research and commercializes innovative drugs for the treatment of oncology, infectious and autoimmune diseases. BJ Bioscience is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of BJ-005’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
